Skip to content
Biotech Industry Examiner
News
Funding
Aging Science
Genomics
Explore Our Network
Industry Examiner
Fintech
Agtech
Spacetech
Climatetech
News
Funding
Aging Science
Genomics
Explore Our Network
Industry Examiner
Fintech
Agtech
Spacetech
Climatetech
Menu
News
Funding
Aging Science
Genomics
Explore Our Network
Industry Examiner
Fintech
Agtech
Spacetech
Climatetech
Menu
M&A & Partnerships
Biotech Stocks
AI in Biotech
CRISPR
Food Biotech
Insights
Longevity
Neuroscience
Precision Medicine
Psychology
Startup
Aging Science
AI in Biotech
Biotech Stocks
CRISPR
Food Biotech
Funding
Genomics
Insights
Longevity
M&A & Partnerships
Neuroscience
News
Precision Medicine
Psychology
Startup
Explore Our Network
Industry Examiner
Fintech
Agtech
Spacetech
Climatetech
subscribe now
Search
Search
Innovative Study on Addiction by Mount Sinai and Rockefeller University
A recent study conducted by Mount Sinai in collaboration with
Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case
Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?
The FDA wants to “pre-check” factories before the medicine exists
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear
Obesity’s next arms race: staying power, not just weight loss
MOST POPULAR
Texas Ban on Lab-Grown Meat Triggers Policy and Legal Showdowns
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
Dermatology’s next play: bispecifics that shut down OX40L and TNF
Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030?
The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer
The patch that could unstick vaccination: Vaxxas’s A$90m bet on needle-free delivery
News
The FDA wants to “pre-check” factories before the medicine exists
Obesity’s next arms race: staying power, not just weight loss
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
Funding
The patch that could unstick vaccination: Vaxxas’s A$90m bet on needle-free delivery
From Platform to Precision: The $800M Bet Transforming Biotech Investing
Draupnir Bio Raises €12 Million to Advance Oral Protein Degraders Targeting Extracellular Proteins
Novo Holdings Leads $100 Million Series C Financing for Asceneuron
German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies
Brisbane Biotech Gelomics Raises $2.2 Million in Pre-Seed Funding
Aging Science
The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show
Genomics
From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care
The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer
Epigenetic Stability Linked to Lifespan in Mammals, Research Show
Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development
AstraZeneca Completes Equity Investment in Cellectis to Enhance Gene Therapy Development
Innovative Breakthrough in Genomics: Profluent’s OpenCRISPR-1 Revolutionizes Human Genome Editing
M&A & Partnerships
Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear
Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier
Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines
Biotech Stocks
Illumina’s Market Struggles Deepen as U.S.-China Tensions Escalate
Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion
Alumis IPO Priced at $16, Targets $210M Funding
Diamond Biofund Becomes First Biotech VC Firm Listed on Taiwan Stock Exchange
Psychology
Innovative Study on Addiction by Mount Sinai and Rockefeller University
Scroll to Top
